Studies of Aβ Pharmacodynamics in the Brain, Cerebrospinal Fluid, and Plasma in Young (Plaque-Free) Tg2576 Mice Using the γ-Secretase Inhibitor N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N 1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl] -L-alaninamide (LY-411575)

Journal of Pharmacology and Experimental Therapeutics

Volumn 309, Issue 1, 2004, Pages 49-55

  Lanz, Thomas A ^a   Hosley, John D ^a   Adams, Wade J ^a   Merchant, Kalpana M ^a,b  

^a PFIZER INC   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; LY 411575; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYETHANOYL] N1 (5 METHYL 6 OXO 6,7 DIHYDRO 5H DIBENZO[B,D]AZEPIN 7 YL)ALANINAMIDE; UNCLASSIFIED DRUG; ALANINE; ASPARTIC PROTEINASE; AZEPINE DERIVATIVE; BACE1 PROTEIN, HUMAN; BACE1 PROTEIN, MOUSE; DRUG DERIVATIVE; ENZYME INHIBITOR; N2 ((2S) 2 (3,5 DIFLUOROPHENYL) 2 HYDROXYETHANOYL) N1 ((7S) 5 METHYL 6 OXO 6,7 DIHYDRO 5H DIBENZO(B,D)AZEPIN 7 YL) L ALANINAMIDE; N2-((2S)-2-(3,5-DIFLUOROPHENYL)-2-HYDROXYETHANOYL)-N1-((7S)-5-METHYL-6-OXO-6,7-DIHYDRO-5H-DIBENZO(B,D)AZEPIN-7-YL)-L-ALANINAMIDE; PROTEINASE; SECRETASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE MARKER; ENZYME INHIBITION; FEMALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSGENIC MOUSE; ANIMAL; BLOOD; BRAIN; DOSE RESPONSE; DRUG EFFECT; HUMAN; MALE; METABOLISM; SENILE PLAQUE; TIME;

ALANINE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ENDOPEPTIDASES; AZEPINES; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPEPTIDASES; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MICE; SENILE PLAQUES; TIME FACTORS;

EID: 1642296212     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.060715     Document Type: Article

References (23)

1. Cirrito JR, May PC, O'Dell MA, Taylor JT, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KB, Paul SM, et al. (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J Neurosci 23:8844-8853.
2. Deane R, Yan SD, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, et al. (2003) RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9:907-913.
3. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, and Holtzman DM (2001) Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98:8850-8855.
4. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, and Holtzman DM (2002) Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science (Wash DC) 295:2264-2267.
5. Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ, et al. (2001) Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 76:173-181.
6. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, and Cole G (1996) Correlative memory deficits, Abeta elevation and amyloid plaques in transgenic mice. Science (Wash DC) 274:99-102.
7. Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, Sandbrink R, Masters CL, and Beyreuther K (1996) Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 271:22908-22914.
8. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, and Younkin SG (2001) Age-dependent changes in brain, CSF and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21:372-381.
9. Kuo Y, Kokjohn TA, Kalback W, Luehrs D, Galasko DR, Chevallier N, Koo EH, Emmerling MR, and Roher A (2000) Amyloid-β peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem Biophys Res Commun 268:750-756.
10. Lanz TA, Himes CS, Pallante G, Adams L, Yamazaki S, Amore B, and Merchant KM (2003) The γ-secretase inhibitor, DAPT, reduces Aβ levels in vivo in plasma and CSF in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther 305:864-871.
11. Lewis HD, Revuelta BIP, Nadin A, Neduvelil JG, Harrison T, Pollack SJ, and Shearman MS (2003) Catalytic site-directed γ-secretase complex inhibitors do not discriminate pharmacologically between notch S3 and β-APP cleavages. Biochemistry 42:7580-7586.
12. Li J, Fici GJ, Mao CA, Myers RL, Shuang R, Donoho GP, Pauley AM, Himes CS, Qin W, Kola I, et al. (2003) Positive and negative regulation of the γ-secretase activity by nicastrin in a murine model. J Biol Chem 278:33445-33449.
13. Maness LM, Banks WA, Podlisny MB, Selkoe DJ, and Kastin AJ (1994) Passage of human amyloid β-protein 1-40 across the murine blood-brain barrier. Life Sci 55:1643-1650.
14. Martel CL, Mackic JB, McComb JG, Ghiso J, and Zlokovic BV (1996) Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid beta in guinea pigs. Neurosci Lett 206:157-160.
15. Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, and Games D (1996) Comparison of neurodegnerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J Neurosci 16:5795-5811.
16. Matsubara E, Ghiso J, Frangione B, Amari M, Tomidokoro Y, Ikeda Y, Harigaya Y, Okamoto K, and Shoji M (1999) Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. Ann Neurol 45:537-541.
17. Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, and Duff K (2003) Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 23:29-33.
18. May PC, Alstiel L, Bender MH, Boggs LN, Calligaro DO, Fuson KS, Gitter BD, Hyslop PA, Jordan WH, Li WY, et al. (2001) Marked reduction of Abeta accumulation and beta-amyloid plaque pathology in mice upon chronic treatment with a functional gamma-secretase inhibitor. Soc Neurosci Abstr 27:687.1.
19. Mehta PD, Dalton AJ, Mehta SP, Kim KS, Sersen EA, and Wisniewski HM (1998) Increased plasma amyloid beta protein 1-42 levels in Down syndrome. Neurosci Lett 241:13-16.
20. Poduslo JF, Curran GL, Sanyal B, and Selkoe DJ (1999) Receptor-mediated transport of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier. Neurobiol Dis 6:190-199.
21. Savage MJ, Trusko SP, Howland DS, Pinsker LR, Mistretta S, Reaume AG, Greenberg BD, Siman R, and Scott RW (1998) Turnover of amyloid β-protein in mouse brain and acute reduction of its level by phorbol ester. J Neurosci 18:1743-1752.
22. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, and Swindlehurst C (1992) Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature (Lond) 359:325-327.
23. Zlokovic BV, Ghiso J, Mackic JB, McComb JG, Weiss MH, and Frangione B (1993) Blood-brain barrier transport of circulating Alzheimer's amyloid beta. Biochem Biophys Res Commun 197:1034-1040.